💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

MiMedx responds (again) to allegations of channel stuffing; conference call tomorrow to update investors

Published 09/20/2017, 04:14 PM
© Reuters.  MiMedx responds (again) to allegations of channel stuffing; conference call tomorrow to update investors
MDXG
-
  • MiMedx (NASDAQ:MDXG) issues a new statement to address two new short seller articles that appeared today, one by Viceroy Research and the other by Aurelius Value.
  • CEO Pete Petit says, The articles include several items that have virtually no basis in fact, are littered with innuendo and contain many statements that are simply not correct. This has all the markings of a concerted short seller attack by numerous entities attempting to short our stock and profit from fictitious information and innuendos. We believe that Viceroy Research and Aurelius Value are relying on misinformation from former MiMedx employees terminated for cause. Unfortunately, neither organization appears to have done adequate due diligence and fact-finding before publishing their so-called 'research reports.' We have scheduled a shareholder call tomorrow, Thursday, September 21st, at 10:30 am Eastern Time to discuss various topics on the Company's extremely positive performance and trajectory for future growth. We will also address this orchestrated short seller activity and the remedies the Company is seeking to have this unlawful practice of pushing fabricated information to shareholders in concert with coordinated short selling activity cease."
  • The company issued an earlier statement on August 17 addressing the whistleblower suit.
  • Previously: MiMedx under pressure on bearish Aurelius report, shares down 2% (Sept. 20)
  • Previously: MiMedx still dogged by attorney representing former employees in alleged channel-stuffing litigation; shares down 3% (Sept. 7)
  • Previously: MiMedx says it is on the right side of litigation with former employees (Aug. 17)
  • Now read: BioLife Is On The Rise After Earnings - Here's Why


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.